DARE, NASDAQ #Phase 1 #Positive Clinical Trial Results Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause January 26, 2023 08:00 EST Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) — Daré Bioscience, No Comments
ACIU, NASDAQ #Alzheimer #Phase 1 #Trending News AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial January 26, 2023 07:00 EST AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial ACI-24.060 elicited an anti-Abeta antibody response in ABATE’s first, low dose cohort ACI-24.060 was generally well tolerated with no safety concerns observed With these findings, dosing in the second, No Comments
NBIO, OTC #Cancer #Phase 1 Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial January 25, 2023 08:01 EST NORTH PALM BEACH, FL / ACCESSWIRE / January 25, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (Nascent Biotech, Nascent, or the Company), a clinical-stage biotechnology Company developing monoclonal antibodies that target various cancer types, announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety No Comments
NBIO, OTC #Cancer #Phase 1 Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial January 25, 2023 08:00 EST NORTH PALM BEACH, FL / ACCESSWIRE / January 25, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology Company developing monoclonal antibodies that target various cancer types, announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety No Comments
NASDAQ, PGEN #Expansion #Featured #Phase 1 #Positive Clinical Trial Results #Trending News Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis January 24, 2023 16:01 EST – Repeated administrations of PRGN-2012 were well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2 – – Clinical data show strong response in RRP patients with 50% of patients in Complete Response, requiring no post-treatment surgeries, following PRGN-2012 treatment at Dose Level 2; All No Comments
BGAVF, OTC #Drilling Update #Phase 1 Bravada Files Technical Report for the Wind Mountain Au/Ag Project, Nevada, Including Phase I PEA Results of 38% IRR and US$46.1 Million After-Tax [email protected]% January 24, 2023 13:33 EST Vancouver, British Columbia–(Newsfile Corp. – January 24, 2023) – Bravada Gold Corporation (TSXV: BVA) (OTCQB: BGAVF) (FSE: BRTN) (the “Company” or “Bravada”) reports today that it has filed a technical report (the “Report”) prepared in accordance with Canadian Securities Administrators’ National Instrument 43-101 (“NI 43-101”). The Report may be No Comments
ALLO, NASDAQ #Cancer #New Clinical Trial Data #Phase 1 #Trending News Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma January 24, 2023 08:30 EST SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for No Comments
NASDAQ, VTGN #NASA #New Clinical Trial Data #Phase 1 #Trending News Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder January 24, 2023 08:30 EST SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the first cohort of healthy volunteers has been dosed in its U.S. Phase 1 clinical trial No Comments
NASDAQ, RAIN #Cancer #New Clinical Trial Data #Phase 1 #Trending News Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology January 23, 2023 08:00 EST – Intermittent dosing of milademetan, an inhibitor of the p53-MDM2 complex, potentially exhibits an avenue to address historical issues with cytopenias with this class of compounds– – Phase 1 data in advanced dedifferentiated liposarcoma provides foundation for the registrational Phase 3 MANTRA trial – NEWARK, Calif., Jan. 23, 2023 No Comments
MRTX, NASDAQ #Cancer #FDA Clearance #Phase 1 #Trending News Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133 January 19, 2023 17:00 EST IND demonstrates Mirati’s leadership in KRAS, representing the Company’s third KRAS or KRAS-signaling program to enter clinical development SAN DIEGO, Jan. 19, 2023 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of MRTX1133, a No Comments
STEER Announces a Proposed Transaction for an $18 Million Direct Investment Involving its Digital Restaurant Supply Business (B2B Marketplace) 01/23/2023
Ra Medical Systems Announces the Presentation of Clinical Data at the European Heart Rhythm Association Congress 01/23/2023